News from Abide Therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Nov 28, 2017, 07:00 ET Abide Therapeutics Reports Positive Topline Data from Phase 1b Study of ABX-1431 in Tourette Syndrome

Abide Therapeutics, a biopharmaceutical company focused on developing novel therapeutics targeting the serine hydrolase family of enzymes,...


Oct 10, 2017, 08:37 ET Abide Therapeutics Announces Dosing of First Subject in Phase 1b Study of ABX-1431 in Patients with Neuromyelitis Optica (NMO)

Abide Therapeutics, a developer of innovative pharmaceuticals, announced today initiation of dosing in a Phase 1b study to evaluate the effects of...


Sep 18, 2017, 07:00 ET Abide Therapeutics Appoints Dr. Sapna Srivastava As Chief Financial and Strategy Officer

Abide Therapeutics, a developer of innovative pharmaceuticals, announced today the appointment of Sapna Srivastava, Ph.D., to the position of Chief...


May 17, 2017, 08:33 ET Abide Therapeutics to Present at EUFEMED Annual Meeting on ABX-1431 Clinical Program

Abide Therapeutics, a developer of innovative pharmaceuticals, announced today that new preclinical and clinical data on ABX-1431, an...


Dec 14, 2016, 08:00 ET Abide Therapeutics Announces First Patient Dosed in Phase 1b Study to Assess the Effect of ABX-1431 in Patients with Functional Dyspepsia

Abide Therapeutics, a developer of innovative pharmaceuticals, announced today initiation of dosing in a Phase 1b study to evaluate the effects of...


Sep 29, 2016, 08:00 ET Abide Therapeutics Announces Celgene Option Exercise to Develop ABX-1431, an Investigational Endocannabinoid System Modulator for Patients with Neurological Diseases

Abide Therapeutics announced today that Celgene has exercised its option to obtain ex-US rights to Abide's first-in-class endocannabinoid system...


May 10, 2016, 08:00 ET Abide Therapeutics Announces First Subject Dosed In PET Occupancy Study with [18F]ABX-1488, A Proprietary Human Monoacylglycerol Lipase (MGLL)-Specific PET Ligand

Abide Therapeutics, a developer of innovative pharmaceuticals, announced today initiation of enrollment and dosing in a Phase 1 PET occupancy study...


Jan 19, 2016, 08:00 ET Abide Therapeutics Appoints Richard N. Kender to Board of Directors

 Abide Therapeutics announced today the appointment of Richard N. Kender to its Board of Directors. Kender is a consultant to biotechnology...


Jan 06, 2016, 08:00 ET Abide Therapeutics Appoints Dr. Chan Beals As Chief Medical Officer

Abide Therapeutics announced today the appointment of Chan Beals, M.D., Ph.D., to the position of Chief Medical Officer. Dr. Beals has more than 15...


Sep 08, 2015, 08:00 ET Abide Therapeutics Appoints Donald Hertzog as Vice President, Early Lead Identification

 Abide Therapeutics announced today the appointment of Donald Hertzog, Ph.D., as Vice President, Early Lead Identification....


Nov 04, 2014, 08:00 ET Abide Therapeutics Announces a Collaborative Agreement with the University of Oxford

 Abide Therapeutics announced today that the Company has entered into a collaborative agreement with the University of Oxford and the Oxford...


Jul 29, 2014, 08:00 ET Abide Therapeutics Appoints Nancy Thornberry to Board of Directors

 Abide Therapeutics announced today the appointment of Nancy Thornberry to its board of directors. Thornberry was previously senior vice...


Oct 29, 2013, 08:00 ET Abide Therapeutics Appoints Dr. Gary O'Neill as Vice President of Biology

 Abide Therapeutics announces today that Gary O'Neill, Ph.D., has joined Abide Therapeutics as vice president of biology and member of the...


Jul 16, 2013, 08:00 ET Abide Therapeutics and UC San Diego Awarded Grant from Cure Alzheimer's Fund to Validate Therapeutic Target

Confirming an enzyme in the serine hydrolase family as a therapeutic target to slow and potentially reverse the effects of Down syndrome and...


May 02, 2013, 07:30 ET Abide Therapeutics Announces Collaboration With Merck to Develop Novel Therapies for Type 2 Diabetes and Metabolic Diseases

 Abide Therapeutics, a biopharmaceutical company pioneering innovative approaches to selectively target a group of enzymes known as serine...